- ment conference. Washington DC: American Psychiatric Press, 1994: 105-20
144. Wardle J, Hayward P, Higgitt A, et al. Effects of concurrent diazepam treatment on the outcome of exposure therapy in agoraphobia. *Behav Res Ther* 1994; 32: 203-15
 145. Hegel M, Ravaris C, Ahles T. Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. *Behav Ther* 1994; 25: 183-95
 146. Welkowitz LA, Papp LA, Cloitre M, et al. Cognitive-behaviour therapy for panic disorder delivered by psychopharmacologically oriented clinicians. *J Nerv Ment Dis* 1991; 179: 473-7
 147. Otto M, Pollack M, Sachs G, et al. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. *Am J Psychiatry* 1993; 150: 1485-90
 148. Spiegel DA, Bruce TJ, Gregg SF, et al. Does cognitive behaviour therapy assist slow-taper alprazolam discontinuation in panic disorder? *Am J Psychiatry* 1994; 151 (6): 876-81
 149. Barlow DH. Comorbidity in social phobia: implications for cognitive-behavioral treatment. *Bulletin of the Menninger Clinic* 1994; 58 (2 Suppl. A): A43-57
 150. Shear MK, Pilkonis PA, Cloitre M, et al. Cognitive behavioral treatment compared with nonprescriptive treatment of panic disorder. *Arch Gen Psychiatry* 1994; 51 (5): 395-401

Correspondence and reprints: Dr Michael R. Johnson, Department of Psychiatry, Medical University of South Carolina, 171 Ashley Avenue, Charleston, SC 29425, USA.

Addendum

Vol. 47, No. 6, p. 904: In the article 'Parenteral Aminoglycoside Therapy: Selection, Administration and Monitoring' it has been drawn to our attention that footnote 'd' to table I is incomplete. The last sentence of the footnote should read as follows: 'If the required dosage were 1.2 or 0.6 mg/kg/day, then it too would be given as a single daily dose (but see section 4.5)'.
 [CR Kumana, KY Yuen. Parenteral aminoglycoside therapy: selection, administration and monitoring. *Drugs* 1994; 47 (6): 902-913]